Anetumab ravtansine
- Generic Name
- Anetumab ravtansine
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1375258-01-7
- Unique Ingredient Identifier
- M170940PMI
- Background
Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
- Conditions
- Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
- Interventions
- Biological: Anetumab RavtansineProcedure: BiopsyProcedure: Biospecimen CollectionDrug: Gemcitabine HydrochlorideBiological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT03816358
- Locations
- ๐บ๐ธ
The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
๐บ๐ธUniversity of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
๐บ๐ธCity of Hope Comprehensive Cancer Center, Duarte, California, United States
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian Endometrioid AdenocarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaPlatinum-Resistant Ovarian CarcinomaOvarian High Grade Serous Adenocarcinoma
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 96
- Registration Number
- NCT03587311
- Locations
- ๐บ๐ธ
The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
๐บ๐ธUC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
๐บ๐ธUCHealth University of Colorado Hospital, Aurora, Colorado, United States
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
- Conditions
- Pleural Malignant Mesothelioma
- Interventions
- Biological: Anetumab RavtansineOther: Laboratory Biomarker AnalysisBiological: PembrolizumabOther: Pharmacological Study
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 49
- Registration Number
- NCT03126630
- Locations
- ๐บ๐ธ
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
๐บ๐ธMayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
๐บ๐ธUC San Diego Moores Cancer Center, La Jolla, California, United States
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT02839681
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.